Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma

Diaz, J., Sternberg, C.N., Mehmud, F. et al. (4 more authors) (2016) Overall Survival Endpoint in Oncology Clinical Trials: Addressing the Effect of Crossover - The Case of Pazopanib in Advanced Renal Cell Carcinoma. Oncology, 90 (3). pp. 119-126. ISSN 0030-2414

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © 2016 Karger Publishers. This is an author produced version of a paper subsequently published in Oncology. Uploaded in accordance with the publisher's self-archiving policy.
Keywords: Crossover; Overall survival; Pazopanib; Renal cell; Carcinoma
Dates:
  • Published: 16 March 2016
  • Published (online): 23 February 2016
  • Accepted: 23 December 2015
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield) > Sheffield Centre for Health and Related Research
Depositing User: Symplectic Sheffield
Date Deposited: 20 Feb 2017 10:51
Last Modified: 03 Nov 2017 02:54
Published Version: https://doi.org/10.1159/000443647
Status: Published
Publisher: Karger Publishers
Refereed: Yes
Identification Number: https://doi.org/10.1159/000443647

Share / Export

Statistics